An effective blockade of TNFα-dependent cytokine cascades and leukocyte recruitment as well as good clinical and serological response rates have led to the establishment of therapy with TNFα inhibitors in RA and other autoimmune disorders. This evidence concerns the gene TNF and rheumatoid arthritis.